Small reports showed striking regrowth with upadacitinib for alopecia areata. Controlled trials offer a firmer basis for discussing expectations.
On October 30, 2026, AJMC reported on a systematic review of upadacitinib for alopecia areata that pooled small studies showing substantial hair regrowth. The analysis by Barnawi and colleagues was published in the Journal of the American Academy of Dermatology.
AJMC’s account of the review provides these main findings:
Those last two findings deserve separate attention. An improvement from baseline and reaching a particular level of scalp coverage answer different questions. Keeping the endpoints distinct makes a treatment headline more useful than simply describing everyone as having responded.
AJMC also reported results from two later phase 3 placebo-controlled trials in severe alopecia areata. At week 24, SALT ≤20 response rates were 44.6% to 45.2% in the lower-dose groups. The higher-dose groups recorded 54.3% to 55.0%, compared with 1.5% to 3.4% in the placebo groups.
The treatment groups therefore had substantially higher response rates than placebo. But the controlled-trial results were lower than the pooled review’s headline figure. AJMC characterizes those randomized results as a more reliable basis for setting patient expectations.
The useful conclusion is not that the early reports had no value. They identified a promising regrowth signal. The controlled trials gave that signal a stronger test and produced a different picture of how often participants reached the same scalp-coverage endpoint.
These numbers are not a head-to-head comparison. AJMC notes that the pooled evidence largely came from open-label case series or small cohorts without placebo controls, which may overstate outcomes in a broader patient population. That design also limits how much of the observed regrowth or adverse effects can be attributed to the medicine.
AJMC reports that about one-third of people in the pooled studies experienced adverse effects. These were described as mild and did not lead to treatment discontinuation in those reports. The review authors’ description of a “favorable safety profile” reflects that small-study evidence rather than establishing safety for an individual patient.
For men over 35, the pooled group’s age and sex profile also matter when discussing relevance. The review found no statistically significant differences in SALT change by age group or dose grouping or prior JAK-inhibitor failure. Its small total sample does not establish that those factors never affect an individual response.
There is also a separate safety context. MedPage Today explains that the FDA’s JAK-inhibitor class warning followed a study of tofacitinib in older rheumatoid arthritis patients with cardiovascular risk factors. The warning was subsequently extended to other JAK inhibitors. That history is not a personalized risk estimate for someone considering upadacitinib for alopecia areata.
For a gay man over 35, the practical value of this news is a better conversation about hair loss rather than a new product to add to the bathroom shelf. The evidence supports clarifying the condition and discussing treatment goals alongside personal health history and possible risks.
The first useful step is establishing what kind of hair loss is occurring with a dermatologist. According to AJMC’s coverage, the phase 3 results concern severe alopecia areata. They do not concern ordinary thinning or androgenetic hair loss.
That distinction should shape the entire discussion. A compelling response rate for one condition is not a reason to assume the same medicine is suitable for another. Bring the question back to the diagnosis before comparing treatment headlines or deciding which outcome matters to you.
GayFitLab’s coverage of severe alopecia areata offers related reading focused on this specific condition. Keeping that focus is more useful than treating every report about hair regrowth as interchangeable.
Once alopecia areata is diagnosed, ask the dermatologist to connect the evidence to your treatment goals. A scalp-coverage endpoint gives the conversation a concrete reference point. It does not decide which appearance concerns deserve the most attention in your life.
You might care most about scalp coverage or about changes involving eyebrows and eyelashes. Quality of life may also belong in the conversation. Those outcomes appeared in the longer-term research update described by the National Alopecia Areata Foundation, making them relevant subjects to raise rather than assume.
Useful questions for the appointment include:
These questions are a discussion framework, not a treatment protocol. Their purpose is to make the reasoning behind a medical decision easier to follow. Personal prescribing decisions belong with the qualified clinician who can assess your circumstances.
The same reading habit applies across other hair-growth research: identify the condition being studied and the outcome being measured before deciding how relevant the headline is.
The National Alopecia Areata Foundation reported in October 2026 that upadacitinib had approval for alopecia areata in the European Union but was not yet FDA-approved for that indication in the United States. That is the status described at the time of its report, not a universal statement about approval everywhere.
For a treatment discussion, ask which regulatory status applies where you receive care. A report from another jurisdiction should not stand in for that local conversation. Approval status belongs beside the evidence and your health history rather than being treated as a detail to sort out later.
The foundation also reported that AbbVie presented 52-week UP-AA phase 3 analyses at the European Academy of Dermatology and Venereology congress. These addressed longer-term efficacy and safety alongside quality of life and eyebrow and eyelash outcomes. The cited update did not provide numerical results, so it does not support attaching a new response percentage to those longer-term findings.
For your daily routine, the immediate adjustment is about decision-making rather than a new grooming ritual. Establish the diagnosis and make the consultation specific. These findings do not provide a basis for building a supplement routine or changing training around a hair-regrowth headline.
For health span, keep the possible treatment within a broader conversation about your health history and priorities. Scalp coverage is a legitimate outcome to care about. It does not have to become the only outcome through which you judge a medical choice or your appearance.
Wanting more hair does not require an apology. Neither does deciding that treatment is not a priority. Looking polished or feeling attractive need not mean pursuing every available intervention, and a research result does not create an obligation to change your body.
The adult response to promising research is not automatic enthusiasm or automatic dismissal. It is a clearer question about whether the evidence fits the condition and the person. That leaves room for an aesthetic goal without turning a percentage into a promise.
If hair loss concerns you, start with a dermatologist’s diagnosis and use controlled-trial evidence alongside your health history and local approval status to guide any treatment discussion.
A SALT score is more informative beside its study design; GayFitLab translates hair research into practical context for gay men 35+. Its editorial guidance addresses the confusion between beauty marketing and clinical findings, helping readers assess aesthetic claims while keeping appearance and longer-term health in the same conversation.
Stay connected for research-led guidance on fitness, body composition, skin, grooming, vitality, sexual wellbeing, relationships and healthy aging. Clear ideas for gay men 35+ who want to look good, feel strong and age with confidence.
Build habits and systems that support clear thinking, steady energy and long term capacity throughout a demanding career.
explore the Blog
